The stock of GlaxoSmithKline plc (LON:GSK) gapped up by GBX 4 today and has GBX 2108.68 target or 34.00% above today’s GBX 1573.64 share price. The 9 months technical chart setup indicates low risk for the GBX 76.73 billion company. The gap was reported on Nov, 10 by Barchart.com. If the GBX 2108.68 price target is reached, the company will be worth GBX 26.09 billion more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock decreased 1.62% or GBX 25.86 on November 10, hitting GBX 1573.64. About 14.16 million shares traded hands or 42.31% up from the average. GlaxoSmithKline plc (LON:GSK) has risen 4.76% since April 14, 2016 and is uptrending. It has underperformed by 0.89% the S&P500.
GlaxoSmithKline plc (LON:GSK) Ratings Coverage
Out of 28 analysts covering GlaxoSmithKline PLC (LON:GSK), 10 rate it a “Buy”, 3 “Sell”, while 15 “Hold”. This means 36% are positive. GlaxoSmithKline PLC has been the topic of 250 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Kepler Cheuvreux given on Monday, September 14. Bernstein maintained GlaxoSmithKline plc (LON:GSK) on Tuesday, February 16 with “Market Perform” rating. Beaufort Securities maintained the shares of GSK in a report on Tuesday, September 6 with “Buy” rating. The stock of GlaxoSmithKline plc (LON:GSK) earned “Overweight” rating by Barclays Capital on Friday, February 19. As per Monday, November 7, the company rating was maintained by HSBC. The stock of GlaxoSmithKline plc (LON:GSK) has “Neutral” rating given on Monday, October 26 by Natixis. The firm earned “Hold” rating on Monday, December 7 by Jefferies. The firm has “Hold” rating by Deutsche Bank given on Wednesday, May 25. The stock has “Neutral” rating given by JP Morgan on Thursday, April 28. Jefferies maintained the shares of GSK in a report on Friday, August 7 with “Hold” rating.
More news for GlaxoSmithKline plc (LON:GSK) were recently published by: Fool.com, which released: “Better Buy: GlaxoSmithKline plc vs. Eli Lilly and Company” on October 26, 2016. Medgadget.com‘s article titled: “Breast Cancer Drugs Market 2015 – 2021 Key Players : GlaxoSmithKline plc, Sun …” and published on November 10, 2016 is yet another important article.
GlaxoSmithKline plc is a healthcare company. The company has a market cap of 76.73 billion GBP. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. It has a 262.45 P/E ratio. The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.